Stock Review – 23/11: Top Affordable Stocks to Purchase (Charts)

Created on November 23, 2025

Defining “undervalued stock” isn’t entirely straightforward, as it varies by individual preference. Generally, though, it refers to publicly traded companies whose shares fluctuate between $5 and $10. These stocks span various sectors and provide numerous chances to diversify investment portfolios.

Undervalued stocks present enticing growth possibilities for investors who are willing to wait and know what signs to look for. They also allow for exposure to innovative sectors like technology, healthcare, and AI—particularly companies that are poised to disrupt traditional industries but haven’t quite reached a tipping point yet.

When assessing these undervalued stocks, consider the following:

• Look for undervalued stocks managed by teams with proven success in reviving companies.
• Investigate your chosen industry and grasp how inexpensive stocks might affect your products or services.
• Carefully examine balance sheets, and analyze multiple quarters of financial reports to verify that these stocks show low debt levels, rising earnings, and enough cash on hand.
• Create a dedicated portfolio for managing undervalued stocks.

Investors should recognize that inexpensive stocks are often priced low for specific reasons. It’s vital to understand why before committing funds. Potential issues could include financial troubles, operational risks, or legal challenges, all factors that warrant careful consideration. The risk tends to be higher, with increased volatility stemming from lower liquidity.

Here’s a brief list of undervalued stocks that could be worth a look right now:

• Mizuho Financial Group (MFG)
• Türksel Iletisim Hizmetleri (TKC)
• CytomX Therapeutics (CTMX)
• Solid Power (SLDP)
• Epsium Enterprises (EPSM)
• BigBear.ai Holdings Co., Ltd. (BBAI)
• Magnitude International (MAGH)
• Compass (COMP)
• Navitas Semiconductor Corporation (NVTS)
• United States Antimony Corporation (UAMY)

In a prior discussion, we mentioned the potential upsides for Mizuho Financial Group and Türksel Iletisim Hizmetleri.

Mizuho Financial Group (MFG) – Currently holding a long position in MFG between $6.48 and $6.75

The stock initially fell but then rebounded by approximately 7%. While it has since moderated back to entry levels, I’m maintaining my long position.

Türksel Iletisim Hizmetleri (TKC) – Currently holding a long position in TKC from $5.35 to $5.62

TKC saw an increase of over 8% before bouncing back down. It’s back within my entry zone, and I’m sticking with this trade.

CytomX Therapeutics (CTMX) is engaged in biopharmaceuticals with a focus on enhancing cancer treatments through more effective, less toxic drugs, primarily their Probody therapeutic products.

I still feel optimistic about CytomX Therapeutics, even given its subpar performance lately.

Despite reporting $6 million in sales and an earnings loss of $0.09—which wasn’t ideal—I’m hopeful because of the promising early results from CX-801 in advanced melanoma and promising data for CX-2051 in late-stage colorectal cancer. CX-2051 may also show potential for other severe conditions, like liver metastases and KRAS mutations.

CytomX Therapeutics Fundamental Analysis Snapshot

With its price-to-earnings (P/E) ratio at 12.82, CTMX is considered relatively cheap, especially compared to the S&P 500’s P/E of 29.87.

The average analyst price target for CytomX Therapeutics is $7.07, indicating solid upside potential with reasonable downside risk.

CytomX price chart

• The CTMX daily chart illustrates price movements between the downward 38.2% and 50.0% Fibonacci retracement levels.
• It also shows CytomX Therapeutics residing within a horizontal support zone.
• The Bull Bear Power Indicator suggests a bullish trend with an upward line forming.

I’ve established a long position in CytomX Therapeutics between $3.49 and $3.93. Even though the price is under $5.00, the solid cash balance, absence of urgent operational issues, and a promising drug pipeline indicate significant upside potential.

Solid Power (SLDP) is making strides in next-generation solid-state battery technology. Beyond developing all-solid-state battery cells, the company also markets sulfide solid electrolytes to others in the solid-state arena.

So, what makes me optimistic about SLDP following its earnings report?

This year, the revenue hit $18.1 million, marking a $2.4 million increase. Operating expenses have been reduced, and the financial standing is robust, bolstered by market offerings and government contracts. I turned optimistic post-Solid Power’s acquisition of key partnerships with Samsung SDI and BMW, reinforcing faith in the practical use of solid-state battery technology.

Solid Power Fundamental Analysis Snapshot

SLDP’s P/E ratio isn’t currently available.

The average analyst price target for SLDP is $7.00, implying promising upside potential with mitigated downside risks.

Stable electricity price chart

• The SLDP daily chart reflects price behavior beneath a rising Fibonacci retracement line.
• It also indicates that Solid Power is nearing a horizontal support level.
• The Bull Bear Power Indicator remains bearish, although an upward trend seems to be taking shape.

I’ve also established a long position in SLDP between $4.32 and $4.77. While some operational metrics have raised questions, the company appears to be heading in the right direction financially. The strong capital position and recent alliances with firms like Samsung SDI and BMW are likely to generate notable momentum moving forward.

Looking to trade? Here are a few top stock broker options worth considering.